Biography:

In the past Eu Chang Hwang has collaborated on articles with Yang Hyun Cho. One of their most recent publications is Chapter 31 - Novel and Emerging Surveillance Markers for Bladder Cancer. Which was published in journal .

More information about Eu Chang Hwang research including statistics on their citations can be found on their Copernicus Academic profile page.

Eu Chang Hwang's Articles: (2)

Chapter 31 - Novel and Emerging Surveillance Markers for Bladder Cancer

AbstractA high likelihood of recurrence of bladder cancer has made the development of urinary markers a focus of intense pursuit with the hope of decreasing the burden which this disease places on patients and the healthcare system. Interests include the development of a single urinary marker that can be used in place of or as an adjunct to surveillance techniques, as well as identifying a molecular signature for an individual’s disease that can help predict progression, prognosis, and potential therapeutic response. Markers have shown potential value in improving diagnostic accuracy when used as an adjunct to current modalities, risk stratification of patients that could aid the clinician in determining aggressiveness of surveillance, and allowing for a decrease in invasive surveillance procedures. This review discusses the current understanding of emerging biomarkers, including gene signatures and their potential clinical value in surveillance tools, as well as limitations to their incorporation into medical practice.

OncologyUse of the NMP22 BladderChek Test in the Diagnosis and Follow-Up of Urothelial Cancer: A Cross-sectional Study

ObjectivesTo investigate the efficacy of the nuclear matrix protein (NMP) 22 BladderChek test (NMP22BC) in the detection and follow-up of urothelial carcinoma.Material and MethodsA total of 1021 patients who underwent the NMP22BC, cytology, and cystoscopy, were studied. We divided the patients into 2 groups: group I consisted of 597 patients who were being followed up for previous urothelial carcinoma, and group II consisted of 424 patients with hematuria. The sensitivity and specificity of the NMP22BC, cytology, and the combination (NMP22BC + cytology) were compared.ResultsOf the 1021 patients, 131 were diagnosed with urothelial cancer. The overall sensitivities for the NMP22BC, cytology, and the combination were 32.1%, 38.2%, and 52.7%, respectively. In group I, the sensitivity of the NMP22BC was lower than the sensitivity of cytology (22.58% vs 35.5%); there was no difference between the sensitivity of the NMP22BC and that of cytology in group II (40.58% vs 40.58%). For the combination, the sensitivity was greater than that of either test alone in both groups (46.77% and 57.97% in groups I and II, respectively). The sensitivity of the NMP22BC was greater than that of cytology (22.6% vs 13.2%) for low-grade bladder cancer.ConclusionsThe NMP22BC has lower sensitivity than cytology. However, the sensitivity of NMP22BC in low-grade tumors was higher than that of cytology. Therefore, when the NMP22BC is combined with cytology, the sensitivity for detecting urothelial carcinoma is increased, which implies that this combination may be useful in the screening and follow-up of urothelial carcinoma.

Advertisement
Join Copernicus Academic and get access to over 12 million papers authored by 7+ million academics.
Join for free!

Contact us